<DOC>
	<DOCNO>NCT01737008</DOCNO>
	<brief_summary>This phase 1 study drug dacomitinib radiotherapy , without chemotherapy , patient advance squamous cell carcinoma head neck ( SCCHN ) . Dacomitinib oral drug , find active SCCHN patient , block receptor call epidermal growth factor receptor ( EGFR ) . By block signal cancer cell grow , believe stop slow growth tumor cell . The dose escalation phase find best dose well determine safety dacomitinib give radiotherapy without chemotherapy.The dose expansion phase test best dose determine dose escalation phase response rate .</brief_summary>
	<brief_title>Dacomitinib Plus Radiotherapy , With Without Cisplatin Patients With Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description>This phase 1 study investigational drug , dacomitinib , radiotherapy without chemotherapy patient advance squamous cell carcinoma head neck ( SCCHN ) . There proteins found surface cell call receptor receive signal send signal cell grow die . Dacomitinib oral drug block receptor call epidermal growth factor receptor ( EGFR ) find active SCCHN patient . By block signal cancer cell grow , believe stop slow growth tumor cell . The treatment SCCHN usually include chemotherapy radiation . The primary objective study two phase : dose escalation phase dose expansion phase . The dose escalation phase find best dose well determine safety dacomitinib give radiotherapy without chemotherapy.The dose expansion phase test best dose determine dose escalation phase safety response rate . The secondary objective evaluate pharmacokinetic property combination therapy , provide preliminary survival data .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Signed voluntary informed consent provide . Patient willing able comply visit , treatment plan , pharmacokinetics , laboratory test , study procedure . Escalation : Arm A : patient local/locally advance confirmed SCCHN ; candidate radical radiotherapy . Arm B : previously untreated patient , locally advanced , confirmed SCCHN ; candidate radical concurrent cisplatinbased chemoradiation . Expansion : previously untreated patient , locally advanced , confirmed SCCHN ; HPVnegative candidate radical concurrent cisplatinbased chemoradiation.Note : Those primary tumor head neck nasopharynx , skin , unknown exclude . Prior treatment current neoplasm allow ; must receive antineoplastic treatment within 2 year . Treatmentrelated toxicity must recover CTCAE Grade 1 ( v.4.0 ) baseline , except toxicity consider risk . Chronic dysphagia , xerostomia effect result prior surgery consider exclusion criterion . ECOG performance status 01 . Patient must adequate organ function determine : Creatinine clearance ≥ 50 mL/min use formula : Creatinine clearance= [ ( 140age ) x wt ( kg ) x Constant ] /creatinine ( µmol/L ) [ Constant = 1.23 men ; 1.04 woman ] . Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L ; Leukocytes &gt; 3.0 x 109/L ; Hemoglobin &gt; 80 g/L ( &gt; 8 g/dL ) ; Platelets ≥ 100 x 109/L . Total bilirubin ≤ ULN ; AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 x ULN . 12Lead electrocardiogram ( ECG ) normal tracing , clinically nonsignificant change . QTc interval &lt; 480 msec , without history Torsades de Pointes QTc abnormality . Enrollment another clinical trial . Prior trial drug use within 30 day 5 halflives precede first dose study medication . Prior treatment agent target epidermal growth factor receptor Requirement drug highly dependent CYP2D6 metabolism dacomitinib potent CYP2D6 inhibitor [ See Appendix B C ] . Patients take drug cause risk Torsades de Pointes Any acute/chronic medical , psychiatric , laboratory abnormality investigator find could increase risk participation , trial drug administration could interfere trial result . Including : History interstitial lung disease ; uncontrolled hypertension , unstable angina , myocardial infarction , symptomatic congestive heart failure within year , cardiac arrhythmia , diagnosed/suspected congenital long QT syndrome ; cardiovascular vascular disease anti arrhythmic therapy and/or major change medical care within 6 month ; active bacterial , fungal viral infection include hepatitis B C , human immunodeficiency virus . Testing required patient symptoms infection . History bleed disorder , concurrent medication investigator find potentially lead unacceptable coagulation function , include : congenital bleeding disorder ; acquire bleed disorder within one year ; Other serious uncontrolled medical disorder active infection investigator determines may impair ability receive study treatment . Dementia alter mental status limit ability obtain informed consent compliance requirement protocol . Breastfeeding/pregnancy . Females reproductive potential [ female menarche successful surgical sterilization/is postmenopausal ( define amenorrhea &gt; 12 consecutive months/women hormone replacement therapy serum follicle stimulate hormone level &gt; 35 mL.U/mL ) ] require negative pregnancy test within 72 hour treatment . Patients reproductive potential/partners must agree effective contraception receive trial treatment 3 month . Effective contraception judgment principal investigator designate . Inability lack willingness comply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Head neck</keyword>
	<keyword>Squamous cell carcinoma</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Dacomitinib</keyword>
	<keyword>Radiation</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Chemoradiation</keyword>
	<keyword>Chemoradiotherapy</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Maximum tolerate dose</keyword>
	<keyword>Safety</keyword>
	<keyword>Human epidermal growth factor receptor</keyword>
	<keyword>Previously Untreated</keyword>
	<keyword>Local Locally Advanced</keyword>
</DOC>